David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

David A. Williams, MD

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Issues in Oncology

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida.

Moderator: Robert Rifkin, MD
Participants: Corey Cutler, MD; Pere Gascon, MD, PhD; Mark McCamish, MD, PhD

This program is supported by Sandoz Inc.

Leukemia

Sébastien Maury, MD

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study

Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1). To see the French language version of this newsreel, please click here.

Mar

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study

Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening

HPV Vaccination Protection From Cervical Cancer Sustained Long Term

Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma